AtriCure (ATRC, Financial) experienced a notable stock price increase of 5.04%, reaching $36.44, with a trading volume of 258,045 shares and a turnover rate of 0.53%. The stock's fluctuation amplitude was recorded at 4.67%. Recent financial reports show AtriCure's revenue at $116 million, with a net loss of $7.85 million, translating to an earnings per share of -$0.17. The gross profit stood at $86.03 million, and the price-to-earnings ratio was -43.83.
Currently, there are no institutional ratings such as "buy," "hold," or "sell" for AtriCure. Within the medical device sector, where AtriCure operates, the overall increase was 4.12%. Other significant movers in the sector included Microbot Medical Inc., Nexgel, Inc., and Nephros, Inc. Stocks like Glucotrack, Inc., Microbot Medical Inc., and Avinger, Inc. showed notable activity with turnover rates of 603.11%, 17.21%, and 8.59% respectively. High volatility was observed in Microbot Medical Inc., Glucotrack, Inc., and Innovative Eyewear Inc C/Wts, with amplitudes of 24.03%, 19.92%, and 19.26% respectively.
AtriCure Inc is a leader in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company's product range includes cryoablation, soft tissue dissection, and radiofrequency ablation pacing and sensing. AtriCure also offers minimally invasive ablation devices and access tools, primarily generating revenue from the U.S. market.
